Clinical Trial Update: A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy. [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing rifaximin, a probiotic, L-ornithine-L-aspartate, and lactulose for overt hepatic encephalopathy has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overt Hepatic Encephalopathy

Drugs mentioned

• L-ornithine-L-aspartate (L-ornithine-L-aspartate)
• LACTULOSE (Lactulose)
• Probiotic (probiotic)
• Rifaximin (rifaximin)

Snippet

Sponsor: Qurratul Ain Jamil | Conditions: Overt Hepatic Encephalopathy | Phase 4 | Status: COMPLETED